Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;36(7):e502-e505.
doi: 10.1111/jdv.18032. Epub 2022 Mar 3.

Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab

G Pavia  1   2 , L Gargiulo  1   2 , F Spinelli  2 , J Avagliano  2 , M Valenti  1   2 , R G Borroni  1   2 , A Costanzo  1   2 , A Narcisi  2
Affiliations

Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab

G Pavia et al. J Eur Acad Dermatol Venereol. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

A. Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi‐Genzyme, Amgen and Boehringer Ingelheim. A. Costanzo has been consultant and/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz and UCB; R.G. Borroni has been consultant for Almirall and speaker for Abbvie.

Figures

Figure 1
Figure 1
GPP flare presenting in our 47‐year‐old patient: wide erythematous and scaly plaques surrounded by small non‐follicular pustules spreading on the abdomen, both legs and forearms. Scaly and hyperkeratotic plaques involving the face and the scalp.
Figure 2
Figure 2
Clinical presentation at the first access in our Emergency Department (a), at the baseline before starting treatment with risankizumab 75 mg/fl (b) and finally after 16 weeks (c): for each time point both the anterior and posterior surface of the body are shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sun Q, Fathy R, McMahon DE, Freeman EE. COVID‐19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide. Dermatol Clin 2021. 10.1016/j.det.2021.05.016. - DOI - PMC - PubMed
    1. McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after Moderna and Pfizer COVID‐19 vaccination: A registry based study of 414 cases. J Am Acad Dermatol 2021; 85(1): 46–55. - PMC - PubMed
    1. Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. New‐onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019. JAAD Case Rep 2020; 6(12): 1360–1362. 10.1016/j.jdcr.2020.10.013. - DOI - PMC - PubMed
    1. Bostan E, Elmas L, Yel B, Yalici‐Armagan B. Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID‐19 vaccines: A report of two cases. Dermatol Ther 2021:e15110. doi: 10.1111/dth.15110. Epub ahead of print. PMID: 34427024. - DOI - PMC - PubMed
    1. Krajewski PK, Matusiak Ł, Szepietowski JC. Psoriasis flare‐up associated with second dose of Pfizer‐BioNTech BNT16B2b2 COVID‐19 mRNA vaccine. J Eur Acad Dermatol Venereol 2021;35:e632‐e634. - PMC - PubMed